The treatment pen, called Metroject, is already a first-line treatment for rheumatoid arthritis in Europe and America.

Hyphens Pharma has gained exclusive rights to commercialise an autoinjector pen for the treatment of rheumatoid arthritis, called Metoject, in Singapore, Malaysia, Philippines and Vietnam. 

The pharmaceutical company has entered into a marketing and distribution agreement with medac Gesellschaft für klinische Spezialpräparate. Metoject is currently a first-line treatment for rheumatoid arthritis under both European and American guidelines. 

It is already commercialised in over 15 countries in Europe, US and Japan. 

Hyphens Pharma says that this agreement will not have a material effect on the net tangible assets or earnings per share of the group for the financial year ending Dec 31, 2025. 

Shares in Hyphens Pharma closed 0.5 cents lower or 1.754% down at 28 cents on March 11.